期刊文献+

带状疱疹的早期综合治疗 被引量:29

EARLY COMPREHENSIVE TREATMENT ON HERPES ZOSTER
下载PDF
导出
摘要 目的:通过对带状疱疹的早期诊断及早期综合治疗,观察其对急性期疼痛缓解及后遗痛预防的疗效。方法:36例带状疱疹急性期病例随机分成治疗组及对照组,治疗组采用抗病毒药物、曲马多、加巴喷丁、局部神经阻滞及超激光照射治疗。对照组采用抗病毒药物、布洛芬缓释胶囊、局部神经阻滞及超激光照射治疗。采用VAS评分及睡眠影响指数(SIS)对疼痛程度及患者生活质量进行评价。结果:治疗前,治疗组VAS及SIS平均为6.81±1.76及6.62±1.86,对照组VAS及SIS平均为6.57±1.45及6.43±1.75;治疗五周后,治疗组VAS及SIS平均为1.38±1.47及1.02±1.71,对照组VAS及SIS平均为2.27±0.92及2.00±0.65。治疗组后遗痛的发生率为4.8%,对照组为13.3%。结论:带状疱疹的早期诊断及综合治疗不仅可以减轻急性症状,还可减少带状疱疹后神经痛(PHN)的发生率。 Objective: To evaluate the effects of the early diagnosis and comprehensive treatment on the pain score of acute phase of zoster and the incidence rate of postherpetic neuralgia. Methods :36 patients with Herpes Zoster were randomly divided into treatment group and control group. The treatment group was given comprehensive treatment with antiviral drug, tramadol, gabapentin, local nerve block and super laser irradiation, while the control group was only treated with antiviral drug, ibuprofen, local nerve block and super laser irradiation. The effect was evaluated by visual analogue scale (VAS) and sleep interference score(SIS). Results: VAS and SIS of the treatment group were 6.81 ± 1.76 and 6.62 ± 1.86 respectively before treatment, and the control group were 6.57 ±1.45 and 6.43 ± 1.75 respectively. After treatment for 5 weeks, VAS was decreased to 1.38 ± 1.47 and SIS was decrease to 1.02± 1.71 in treatment group, while VAS was decreased to 2.27 ±0.92 and SIS was decrease to 2.00 ± 0.65 in control group. The incidence of postherpetic neuralgia (PHN) in study group was 4.8% and 13.3% in the control group. Conclusion : The efficacy of early diagnosis and comprehensive treatment on Herpes Zoster not only relieve the acute symptoms, but also reduce the incidence of PriN.
出处 《中国疼痛医学杂志》 CAS CSCD 2011年第5期294-297,共4页 Chinese Journal of Pain Medicine
基金 上海交通大学医学院麻醉学重点学科基金资助
关键词 带状疱疹 带状疱疹后神经痛 曲马多 加巴喷丁 Herpes Zoster Postherpetic neuralgia Tramadol Gabapentin
  • 相关文献

参考文献12

  • 1Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain, 1996, 67 : 241 - 251.
  • 2Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CPN, ed. Herpes Zoster and Postherpetic Neuralgia. Amsterdam : Elsevier, 2001, 39 - 65.
  • 3Schmader K, Gnann JW Jr, demiological, clinical, and for the herpes zoster vaccine Watson CP. The epi- pathological rationale J Infect Dis, 2008,197(Suppl 2) :S207 -S215.
  • 4Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain,2008, 9(Suppl 1):S37 -S44.
  • 5Johnson RW. Zoster-associated pain:what is known, who is at risk and how can it be managed? Herpes, 2007, 14(Suppl 2) - 30 -34.
  • 6Kost RG, Straus SE. Postherpetic neuralgia - path-ogenesis, treatment, and prevention. N Engl J Med, 1996,335: 32-42.
  • 7Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect, 2009,137 : 38 -47.
  • 8Stein AN, Britt H, Harrison C, et al. Herpes zos- ter burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine,2009,27 : 520-529.
  • 9Russell ML, Schopflocher DP, Svenson L, et al. Secular trends in the epidemiology of shingles in Al- berta. Epidemiol Infect, 2007,135:908 -913.
  • 10Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging, 2008, 25:991-1006.

同被引文献218

引证文献29

二级引证文献134

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部